Community Bank N.A. Has $2.65 Million Holdings in Elevance Health, Inc. $ELV

Posted by on May 13th, 2026

Community Bank N.A. lessened its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 15.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 7,553 shares of the company’s stock after selling 1,342 shares during the period. Community Bank N.A.’s holdings in Elevance Health were worth $2,648,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Physician Wealth Advisors Inc. boosted its stake in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares in the last quarter. Activest Wealth Management increased its position in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC lifted its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after purchasing an additional 44 shares during the last quarter. ORG Partners LLC lifted its stake in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health in the fourth quarter valued at approximately $38,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV stock opened at $393.12 on Wednesday. The company has a market capitalization of $85.37 billion, a P/E ratio of 16.72, a PEG ratio of 2.17 and a beta of 0.66. The company has a fifty day moving average price of $316.48 and a 200-day moving average price of $332.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $412.96.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. JPMorgan Chase & Co. raised their price objective on Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Robert W. Baird boosted their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Evercore upped their target price on Elevance Health from $345.00 to $360.00 in a report on Thursday, April 23rd. Finally, Barclays increased their target price on Elevance Health from $393.00 to $408.00 and gave the company an “overweight” rating in a research report on Friday, April 24th. Thirteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $384.58.

Check Out Our Latest Analysis on ELV

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Featured Articles

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.